495eP Autoantibody profiling delineates response to combined MEK and RTKs inhibition in KRAS-mutant non-small cell lung cancer

Developing effective therapies for KRAS-mutant non–small cell lung cancer (NSCLC) remains challenging. Although the combined use of the MEK inhibitor trametinib and the RTK inhibitor anlotinib has shown promising preclinical and clinical activity, reliable biomarkers to predict treatment response are still lacking.

Authors

Publication Details

Journal
ESMO Open
Published
2026-03-17
DOI
https://doi.org/10.1016/j.esmoop.2026.106809
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

495eP Autoantibody profiling delineates response to combined MEK and RTKs inhibition in KRAS-mutant non-small cell lung cancer

H. Zhong, M. Hu, B. Han, J. Lu
ESMO Open
Lung Cancer Treatments and Mutations
article

495eP Autoantibody profiling delineates response to combined MEK and RTKs inhibition in KRAS-mutant non-small cell lung cancer

H. Zhong, M. Hu, B. Han, J. Lu
article en

Abstract

Developing effective therapies for KRAS-mutant non–small cell lung cancer (NSCLC) remains challenging. Although the combined use of the MEK inhibitor trametinib and the RTK inhibitor anlotinib has shown promising preclinical and clinical activity, reliable biomarkers to predict treatment response are still lacking.

ESMO OpenVol. 11
Good health and well-being
Openalex Percentile: Top 19%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.